Parallax Volatility Advisers
AERI

Parallax Volatility Advisers’s Aerie Pharmaceuticals AERI Stock Holding History

Parallax Volatility Advisers’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,000
Closed -$35K – 4152
2015
Q3 		$35K Buy
+2,000
New +$36.2K ﹤0.01% 2266

Other funds holding AERI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Parallax Volatility Advisers's AERI Position: Q3 2018 in Review

Parallax Volatility Advisers sold out of Aerie Pharmaceuticals (AERI) in Q3 2018, closing a stake of 61,946 shares — an estimated $4.18M sold.

Parallax Volatility Advisers first reported a position in AERI in Q4 2017 and held it in 2 quarters. The position peaked at $4.18M in Q2 2018. 176 funds tracked by Wall St. Rank hold AERI as of Q3 2018.

  • Parallax Volatility Advisers reported no remaining Aerie Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Parallax Volatility Advisers sold 61,946 Aerie Pharmaceuticals shares in Q3 2018, an estimated $4.18M.
  • Parallax Volatility Advisers first reported a position in Aerie Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Parallax Volatility Advisers's Aerie Pharmaceuticals position peaked at $4.18M in Q2 2018.
  • 176 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2018.

Based on Parallax Volatility Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.